SCHEMBL21628890

SCHEMBL21628890

CNC(=O)c1ccc(Oc2ccc(C3CCCCCC3)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.65
HPGD P15428 1/20 0.65
TSHR P16473 1/20 0.65
HTT P42858 1/20 0.65
MMP13 P45452 3/20 0.58
HDAC8 Q9BY41 2/20 0.58
HDAC6 Q9UBN7 2/20 0.58
HDAC1 Q13547 1/20 0.58
DEGS1 O15121 2/20 0.52
HDAC3 O15379 1/20 0.52
HDAC11 Q96DB2 1/20 0.52
PLK1 P53350 2/20 0.50
HRH3 Q9Y5N1 1/20 0.50
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
HAO1 Q9UJM8 1/20 0.48
NAMPT P43490 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
STAT3 P40763 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21628615 1.00 SMN1; SMN2 (0.65) SMN1; SMN2HPGDTSHRHTTMMP13
SCHEMBL21628764 0.98 SMN1; SMN2 (0.67) SMN1; SMN2HPGDTSHRHTTMMP13
SCHEMBL21628888 0.95 SMN1; SMN2 (0.67) SMN1; SMN2HPGDTSHRHTTMMP13
SCHEMBL21628388 0.92 HPGD (0.71) SMN1; SMN2HPGDTSHRHTTMMP13
SCHEMBL10283170 0.91 HDAC8 (0.69) SMN1; SMN2HPGDTSHRHTTHDAC8
SCHEMBL21628811 0.87 HDAC6 (0.79) SMN1; SMN2MMP13HDAC8HDAC6HDAC1
SCHEMBL21628395 0.87 HDAC6 (0.79) SMN1; SMN2MMP13HDAC8HDAC6HDAC1
SCHEMBL21628682 0.85 HDAC6 (0.81) SMN1; SMN2HPGDTSHRHTTMMP13
SCHEMBL21628400 0.85 HRH3 (0.58) SMN1; SMN2HPGDTSHRHTTHDAC8
SCHEMBL21656481 0.84 ALDH1A1 (0.60) SMN1; SMN2HPGDTSHRMMP13HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600696-B2 Aromatic compounds Xeniopro GmbH (DE) 2026-04-14 US disclosed
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-12-21 US disclosed
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2023-05-18 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-11591289-B2 Aromatic compounds Xeniopro GmbH (DE) 2023-02-28 US disclosed
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2022-11-03 US disclosed
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2021-04-15 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS Xeniopro GmbH (DE) 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150923-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885HPGD 2579/4885TSHR 3747/4885
US-20220348535-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885HPGD 2579/4885TSHR 3747/4885
US-11591289-B2 Aromatic compounds AHR, TYR, MUSK SMN1; SMN2 1107/4885HPGD 2313/4885TSHR 3622/4885
US-20210107863-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885HPGD 2579/4885TSHR 3747/4885
US-12600696-B2 Aromatic compounds CCR1, CCRL2, AHR SMN1; SMN2 919/4885HPGD 3694/4885TSHR 719/4885
US-20230406814-A2 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885HPGD 2579/4885TSHR 3747/4885
US-20200031763-A1 NOVEL AROMATIC COMPOUNDS AHR, TYR, MUSK SMN1; SMN2 796/4885HPGD 2579/4885TSHR 3747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.